The FDA has granted fast track designation (FTD) to LBL-034, an investigational GPRC5D/CD3 bispecific T-cell engager (BiTE), for patients with relapsed/refractory multiple myeloma (R/R MM). This asymmetric design facilitates high-avidity binding to myeloma cells while maintaining controlled activation of T cells to maximize antitumor efficacy while mitigating common immunotherapy complications, such as cytokine release syndrome (CRS) and T-cell exhaustion. A step-up dosing strategy of 10 to 80 μg/kg was used starting from the 80 μg/kg dose. Across the 400 to 1200 μg/kg dose levels (n = 40), the 12-month progression-free survival (PFS) rate was 61.2% at a median follow-up of 9.6 months. Leads Biolabs’ GPRC5D/CD3 bispecific T-Cell engager LBL-034 earns FDA fast track designation—accelerating launch of potential best-in-class therapy for relapsed/refractory multiple myeloma.